A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

Phillip M. Rappold,Lynda Vuong,Josef Leibold,Nicholas H. Chakiryan,Michael Curry,Fengshen Kuo,Erich Sabio,Hui Jiang,Briana G. Nixon,Ming Liu,Anders E. Berglund,Andrew W. Silagy,Eduardo A. Mascareno,Mahdi Golkaram,Mahtab Marker,Albert Reising,Alexander Savchenko,John Millholland,Ying-Bei Chen,Paul Russo,Jonathan Coleman,Ed Reznik,Brandon J. Manley,Irina Ostrovnaya,Vladimir Makarov,Renzo G. DiNatale,Kyle A. Blum,Xiaoxiao Ma,Diego Chowell,Ming O. Li,David B. Solit,Scott W. Lowe,Timothy A. Chan,Robert J. Motzer,Martin H. Voss,A. Ari Hakimi
DOI: https://doi.org/10.1158/2159-8290.cd-21-0925
IF: 28.2
2022-01-01
Cancer Discovery
Abstract:It is poorly understood how the tumor immune microenvironment infl uences dis-ease recurrence in localized clear-cell renal cell carcinoma (ccRCC). Here we per-formed whole-transcriptomic profi ling of 236 tumors from patients assigned to the placebo-only arm of a randomized, adjuvant clinical trial for high-risk localized ccRCC. Unbiased pathway analysis identifi ed myeloid-derived IL6 as a key mediator. Furthermore, a novel myeloid gene signature strongly correlated with disease recurrence and overall survival on uni-and multivariate analyses and is linked to TP53 inactivation across multiple data sets. Strikingly, effector T-cell gene signatures, infi ltration pat-terns, and exhaustion markers were not associated with disease recurrence. Targeting immunosuppres-sive myeloid infl ammation with an adenosine A2A receptor antagonist in a novel, immunocompetent, Tp53-inactivated mouse model signifi cantly reduced metastatic development. Our fi ndings suggest that myeloid infl ammation promotes disease recurrence in ccRCC and is targetable as well as provide a potential biomarker-based framework for the design of future immuno-oncology trials in ccRCC.SIGNIFICANCE: Improved understanding of factors that infl uence metastatic development in localized ccRCC is greatly needed to aid accurate prediction of disease recurrence, clinical decision-making, and future adjuvant clinical trial design. Our analysis implicates intratumoral myeloid infl ammation as a key driver of metastasis in patients and a novel immunocompetent mouse model.
What problem does this paper attempt to address?